# Cambridge Cognition report significant contract for sizeable later stage clinical trial

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-report-significant-contract-for-sizeable-later-stage-clinical-trial/4121129144
- Published: 2023-10-11T07:11:26+01:00
- Author: Jacob Brown

**Cambridge Cognition** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has announced
that it has secured a significant contract for a sizeable later stage clinical trial,
following a competitive tender. The contract combines the Company’s proprietary 
CANTAB^(®) touch-screen cognitive assessments with verbal assessments from its recent
Winterlight Labs acquisition, for the first time.  Additionally, the Company will
supply its electronic Clinical Outcome Assessments (“eCOA”) and provide full training
for clinicians, together with quality control services.

This initial contract is valued at approximately £1 million and revenue is expected
to be recognised over a two-year period, starting in 2023. There is potential for
a further contract with the same customer, of slightly higher value, in 2024 once
the initial results have been analysed from this trial.

Cambridge Cognition and its Winterlight business are recognised as world leaders
in accurate cognitive assessment for neurodegenerative disease trials.  Having acquired
Winterlight in January 2023, Cambridge Cognition developed an integrated front-end
within the first few months post-acquisition and now offers the broadest proprietary
solution for touchscreen and voice assessments in clinical trials.  Cambridge Cognition
is the only company that can offer this unique set of cognitive assessments and 
eCOA as a single vendor solution.

> **Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition said:**
> “Cambridge Cognition acquired Winterlight to have the broadest offering on the
> market. With this contract win, we are realising the benefits of the acquisition.
> We’re excited to be providing full clinical assessment services for a large clinical
> trial to a new customer, that we would have been unlikely to win without having
> made the Winterlight acquisition.  We can expect to win more contracts like this
> over time as we continue to commercialise the combined solutions.”

Share on: